Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal polysaccharide vaccine groups A + C + Y + W-135
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**Meningococcal polysaccharide vaccine groups A + C + Y + W-135** is a tetravalent vaccine consisting of purified capsular polysaccharides from four *Neisseria meningitidis* serogroups (A, C, Y, W-135)[1][2][5]. It is designed to induce active immunity against invasive meningococcal disease by stimulating the production of protective antibodies (IgG, IgM, IgA)[2][5]. The capsular polysaccharides, derived from each serogroup, are purified and formulated in a lyophilized form, stabilized with lactose, and administered intramuscularly after reconstitution[1]. The vaccine may be unconjugated (plain polysaccharide vaccine) or conjugated to carrier proteins (diphtheria toxoid, CRM197, or tetanus toxoid) to improve immunogenicity, durability of immunity, and effectiveness in young children[2][4][5]. It is indicated for the prevention of meningococcal disease in individuals at risk, including those in endemic regions, college students, military recruits, and travelers[2][4].
- Brand names
- NmVac4-A/C/Y/W-135MenactraMenveoMenQuadfi
- Other names
- tetravalent meningococcal polysaccharide vaccineMenACYWMen-C-ACYW-135Men-C-ACYW135Men-C-ACYW 135quadrivalent meningococcal vaccinemeningococcal vaccine A + C + Y + W-135
02
Targets
MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideNmA CPS (Neisseria meningitidis group A capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal polysaccharide vaccine groups A + C + Y + W-135.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal polysaccharide vaccine groups A + C + Y + W-135.